M+W Group wins major contract for Merck’s pharmaceutical facility in China

German engineering group will be responsible for design, procurement, construction management and validation services

M+W Group, a leading high-tech engineering and construction company headquartered in Stuttgart, Germany, has won a major order from Merck for its new pharmaceutical facility in China. The site of around 40,000m2 is located in the Nantong Economical Technological Development area in the Greater Shanghai region. M+W Group will be responsible for the engineering design, procurement, construction management and validation services of the factory including production and support buildings.

The new facility will manufacture multiple types of dry forms of oral solid dosage in their final packaging for the Chinese market, focusing on Merck’s treatments for diabetes, cardiovascular diseases and thyroid disorders. Production capacity is planned to reach more than two billion tablets a year in the first phase, going operational by the end of 2016.

The total building area is about 38,000m2, including a 23,000m2 production building, as well as 9,000m2 allocated to warehousing and logistics. Both are dedicated to high level cGMP activities.

Other buildings will house central utilities, a fire fighting pump station, canteen and offices.

Companies